DIA Research: Advancing the Uses of AI in Biopharmaceutical Development
Phase 1: A Study on the Application and Use of Artificial Intelligence to Support Drug Development
Phase 2: Currently launching! Artificial Intelligence for Adverse Events Prediction
DIA is developing a use case that aims to help further the adoption and implementation of AI in adverse event identification and signal detection. If you are interested in becoming part of the study or learning more, please contact Science@DIAglobal.org.
DIA’s Safety and Pharmacovigilance Certificate Program is a comprehensive, competency-based program designed for individuals new to the field with one to three years of experience, or for those looking to broaden their expertise in this area.